Graffinity
HomeAbout usTechnologyBusinessMediaContactEventsDirections
 
 
Graffinity - fragment screening
 
  Graffinity - fragment based drug discovery
GraffinityGraffinity is the premier partner for fragment based drug discovery and lead development of small molecule pharmaceuticals. Graffinity has built a unique approach which includes chemical microarrays, fragment screening, SPR label-free imaging of protein-ligand interactions, computational chemistry and lead discovery. The technology platform offers a new drug discovery paradigm for the rapid conversion of genomic information into novel, high quality leads and drug candidates.
Graffinity applies this technology in established high-profile collaborations with leading Pharma and Biotech companies.

  Search using keywords  
 
  Print this page Print
 
Latest News
Press Releases:
October 15, 2009:
Graffinity enters into drug discovery research collaboration with Genentech
External Link read more ...
January 26, 2009:
Graffinity and Elan launch fragment-based drug discovery collaboration
External Link read more ...
October 28, 2008:
Graffinity and AstraZeneca enter into multi-target drug discovery alliance
External Link read more ...
September 19, 2008:
Graffinity and EMBL awarded € 0.9 million grant from German Government
External Link read more ...
June 3, 2008:
Graffinity and Rigel enter into drug discovery research alliance
External Link read more ...
External LinkArchive Press Releases
 
 
  Printer Print this page
 
Home | About Us | Technology | Business | Media | Contact | Events | Directions
Site Information |02.09.2010| Visits:30903 | Today:5| User online:1
© 2004-2010Graffinity
All rights reserved. | Top of page